Cargando…
A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
Bevacizumab plus chemotherapy is a well-established first-line treatment for metastatic colorectal cancer (mCRC). We investigated whether polymorphisms of genes involved in immune regulation signaling are related to the clinical outcome of mCRC patients treated with bevacizumab-based chemotherapy. I...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275392/ https://www.ncbi.nlm.nih.gov/pubmed/35837092 http://dx.doi.org/10.3389/fonc.2022.922342 |
_version_ | 1784745476596170752 |
---|---|
author | Qin, Wan Zhao, Ben Wang, Duanrui Liu, Jiamin Zhou, Yilu Zhu, Wenjun Huang, Yongbiao Qiu, Hong Yuan, Xianglin |
author_facet | Qin, Wan Zhao, Ben Wang, Duanrui Liu, Jiamin Zhou, Yilu Zhu, Wenjun Huang, Yongbiao Qiu, Hong Yuan, Xianglin |
author_sort | Qin, Wan |
collection | PubMed |
description | Bevacizumab plus chemotherapy is a well-established first-line treatment for metastatic colorectal cancer (mCRC). We investigated whether polymorphisms of genes involved in immune regulation signaling are related to the clinical outcome of mCRC patients treated with bevacizumab-based chemotherapy. In this study, we genotyped 14 single-nucleotide polymorphisms (SNP) in IFN-γ/IFNGRs/JAKs/STATs/PD-L1 pathway by using DNA from blood samples of 141 mCRC patients treated with first-line bevacizumab-based chemotherapy. In the univariate and multivariate analysis, patients with AA genotype of CD274:rs2297136 had a significantly better PFS and OS than patients with AG or GG genotype (10.8 versus 9.8, log-rank P=0.0031; 31.4 versus 20.9, log-rank P=0.0233). Patients with AG/GG genotype of IFNGR1:rs2234711, CT/TT genotype of IFNGR1:rs9376267 also showed longer OS than patients with AA or CC genotype, however, the statistic did not reach significant after adjusted by clinical factors in the multivariate analysis. A nomogram based on the genetic variants and clinic characteristics was developed with a good accuracy to predict patients’ survival. Our result indicates that CD274:rs2297136 is one of the most important predictors for the prognosis of mCRC patients treated with bevacizumab-based chemotherapy, if further validated in larger population. |
format | Online Article Text |
id | pubmed-9275392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92753922022-07-13 A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy Qin, Wan Zhao, Ben Wang, Duanrui Liu, Jiamin Zhou, Yilu Zhu, Wenjun Huang, Yongbiao Qiu, Hong Yuan, Xianglin Front Oncol Oncology Bevacizumab plus chemotherapy is a well-established first-line treatment for metastatic colorectal cancer (mCRC). We investigated whether polymorphisms of genes involved in immune regulation signaling are related to the clinical outcome of mCRC patients treated with bevacizumab-based chemotherapy. In this study, we genotyped 14 single-nucleotide polymorphisms (SNP) in IFN-γ/IFNGRs/JAKs/STATs/PD-L1 pathway by using DNA from blood samples of 141 mCRC patients treated with first-line bevacizumab-based chemotherapy. In the univariate and multivariate analysis, patients with AA genotype of CD274:rs2297136 had a significantly better PFS and OS than patients with AG or GG genotype (10.8 versus 9.8, log-rank P=0.0031; 31.4 versus 20.9, log-rank P=0.0233). Patients with AG/GG genotype of IFNGR1:rs2234711, CT/TT genotype of IFNGR1:rs9376267 also showed longer OS than patients with AA or CC genotype, however, the statistic did not reach significant after adjusted by clinical factors in the multivariate analysis. A nomogram based on the genetic variants and clinic characteristics was developed with a good accuracy to predict patients’ survival. Our result indicates that CD274:rs2297136 is one of the most important predictors for the prognosis of mCRC patients treated with bevacizumab-based chemotherapy, if further validated in larger population. Frontiers Media S.A. 2022-06-28 /pmc/articles/PMC9275392/ /pubmed/35837092 http://dx.doi.org/10.3389/fonc.2022.922342 Text en Copyright © 2022 Qin, Zhao, Wang, Liu, Zhou, Zhu, Huang, Qiu and Yuan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Qin, Wan Zhao, Ben Wang, Duanrui Liu, Jiamin Zhou, Yilu Zhu, Wenjun Huang, Yongbiao Qiu, Hong Yuan, Xianglin A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy |
title | A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy |
title_full | A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy |
title_fullStr | A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy |
title_full_unstemmed | A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy |
title_short | A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy |
title_sort | genetic variant in cd274 is associated with prognosis in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275392/ https://www.ncbi.nlm.nih.gov/pubmed/35837092 http://dx.doi.org/10.3389/fonc.2022.922342 |
work_keys_str_mv | AT qinwan ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT zhaoben ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT wangduanrui ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT liujiamin ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT zhouyilu ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT zhuwenjun ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT huangyongbiao ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT qiuhong ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT yuanxianglin ageneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT qinwan geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT zhaoben geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT wangduanrui geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT liujiamin geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT zhouyilu geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT zhuwenjun geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT huangyongbiao geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT qiuhong geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy AT yuanxianglin geneticvariantincd274isassociatedwithprognosisinmetastaticcolorectalcancerpatientstreatedwithbevacizumabbasedchemotherapy |